Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy trial targets tough autoimmune cases

NCT ID NCT07583030

First seen May 14, 2026 · Last updated May 20, 2026 · Updated 1 time

Summary

This early-stage study tests a new gene therapy called LVIVO-TaVec400 in people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 44 adults aged 18-65 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS (PMS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.